IncRNA-CD160 decreases the immunity of CD8+ T cells through epigenetic mechanisms in hepatitis B virus infection

JIANSONG WU, QIANG NIU, JIE YUAN, XIAODAN XU and LIUXIA CAO

Department of Infectious Diseases, General Hospital of The Peoples' Liberation Army Rocket Force, Beijing 100088, P.R. China

Received August 15, 2017; Accepted January 7, 2020

DOI: 10.3892/ol.2020.11534

Abstract. The transfer and development of chronic hepatitis B virus (HBV) infection is associated with the T cell immune response, therefore investigating the key regulators of cell immune response is needed to improve chronic HBV treatment. Blood samples from patients with chronic HBV infection were used to confirm the correlation between HBV infection stage and CD160 receptor expression levels in CD8+ T cells, the CD8+ T cells are used to research the mechanism of T cell immune response modulation, moreover, C3H/HeN mice with reduced CD160 expression levels were used to investigate the association between long non-coding (Inc)RNA-CD160 and HBV infection. Long non-coding (Inc)RNA-CD160 and histone-modification enzyme gene histone deacetylase 11 (HDAC11) expression levels were negatively associated with CD160 expression. IncRNA-CD160 can inhibit the secretion of IFN-γ and TNF-α through HDAC11 recruitment and bind to HDAC11 to form a complex on the promoters of IFN-γ and TNF-α. The HDAC11, IFN-γ and TNF-α form a complex and enhance the methylation of H3K9Me1, chromatin changes into the heterochromatin and the transcription of IFN-γ and TNF-α is blocked; moreover, the HDAC11/IFN-γ/TNF-α complex can also inhibit the secretion of IFN-γ and TNF-α in CD160+ CD8+ T cells and suppresses the function of CD8+ T cells. Furthermore, small interfering RNA targeting IncRNA-CD160 can block HBV infection progression. IncRNA-CD160 acts as an immune suppressive factor and is expressed at a high level in peripheral blood CD8+ T cells of HBV infected patients. Furthermore, high expression levels of IncRNA-CD160 can contribute to the inhibition of IFN-γ and TNF-α secretion in CD8+ T cells and decrease the immune response of CD8+ T cells. Therefore, IncRNA-CD160 may become a new target for immunotherapy of chronic HBV infection in the future and may provide a new therapeutic strategy for the treatment of HBV infection.

Introduction

Chronic hepatitis B (CHB) is a serious health problem for humans. Differences in the immune response to hepatitis B virus (HBV) cause different outcomes of HBV infection, in which the cellular immune response of the host plays a critical role in virus clearance (1). In the process of chronic HBV infection, the body's response of T lymphocytes cannot effectively control the virus replication, and the main reason is the functional exhaustion of antiviral CD8+ T cells and CD4+ T lymphocytes (2). The upregulated expression of T cell surface inhibitory receptors is not only a notable feature of T cell functional exhaustion, but is also a key regulatory factor for the reduction of antiviral cytokine secretion, inhibition of the protection of infected target cells and induction of cell apoptosis (3,4). These inhibitory receptors include programmed death 1 (PD-1), cytotoxic T lymphocyte associated antigen 4, T cell immunoglobulin and mucin domain 3, lymphocyte activation gene 3 (LAG-3), CD244 and CD160 (5,6).

Epigenetic programming is the heritable changes of gene regulation without DNA sequence changes, and a previous study has demonstrated that non-coding RNA (ncRNA)-mediated transcriptional and post-transcriptional regulation is an important regulatory mechanism of epigenetic programming (7). A recent study has reported that thousands of long ncRNAs (IncRNAs) participate in the regulation of gene expression during various immune processes, such as the regulation of T cell and dendritic cell differentiation (8). Therefore, the different functions of T cell subpopulations may be regulated by epigenetic programming of
Innate receptors, and lncRNA-regulated epigenetic modifications are a novel mechanism that may explain the diversity and functional plasticity of T cells. However, it is unclear whether and how lncRNAs act as T cell immune response modulators in HBV infection.

CD160, a receptor of immunoglobulin-like activated NK cells, belongs to the glycosylphosphatidylinositol (GPI) membrane protein family. The CD160 gene is located on chromosome 1q42.3, mainly expressed in NK cells and cytotoxic CD8+ T cells, and is not expressed in normal B lymphocytes and EBV transformed B lymphocytes (9). The physiological functions of CD160 include low affinity binding of MHC class I molecules, activation of the PI3K/Akt and ERK signaling pathway, and the promotion of NK cells and CD8+ T to secrete IL-6, IL-8, IFN-γ and TNF-α, which produce cytotoxic effects (10).

Both the ‘Guidelines for the Prevention and Treatment of Chronic Hepatitis B’, edited by the Chinese Medical Association and the Chinese Society of Hepatology Branch of Infectious Diseases, and the ‘Clinical Practice Guidelines’, edited by the European Association for the Study of the Liver in 2012 (11,12), have defined that the natural course of chronic HBV infection can be divided into the immune tolerance (IT) stage, immunological clearance (IC) stage and low-replicate (LR) stage. Since each stage of cellular immunity during chronic HBV infection exhibit their own characteristics, the present study aimed to explore the expression changes of CD160 in T lymphocytes in peripheral blood during chronic HBV infections, and the relationship with the serum virus markers, virus replication and liver damage. Furthermore, the current study investigated whether and how CD160 signaling impacts the host defense against hepatitis B virus infection through regulation of T cell effector function. Additionally, whether the effect of CD160 signaling is associated with epigenetic changes was investigated. The results indicated that CD160 may serve an important inhibitory role in CD8+ T cell function. In addition, lncRNA-CD160 can mediate the TNF-α and IFN-γ secretion in CD8+ T cells and the immunity of CD8+ T cells through epigenetic regulation during hepatitis B virus infection.

Materials and methods

Patients. The patients with chronic HBV infection were defined as hepatitis B surface antigen (HBsAg) positive and/or HBV DNA positive, which was detected in patients for >6 months. The exclusion criteria included liver damage that was caused by hepatitis A virus, hepatitis C virus, cytomegalovirus, drugs or metabolic diseases, and all patients did not receive any immunosuppressive agents or antiviral treatment. The stage of chronic HBV infection was determined according to the ‘Guidelines for the Prevention and Treatment of Chronic Hepatitis B’ by the Chinese Medical Association and the Chinese Society of Hepatology Branch of Infectious Diseases (11). In the present study, 164 patients (mean age 30.6±7.5, and 89 males and 75 females) with chronic HBV infection were selected between January 2015 and June 2016 at the General Hospital of the PLA Rocket Force. Among the 164 patients, 45 were in the IT stage [HBsAg-negative, hepatitis B virus e antigen (HBeAg)-positive, serum HBV DNA load >10^7 copies/ml and normal serum alanine aminotransferase (ALT) level <50 U/l], 61 patients were in IC stage (serum HBV DNA load >10^4 copies/ml and sustained or intermittent rise in the level of ALT >50 U/l) and 58 patients were in LR stage [HBsAg-negative, hepatitis B virus e antibody (HBeAb)-positive, HBV-DNA level remained at the lowest detection threshold <10^3 copies/ml and normal ALT level <50 U/l]. A total of 67 healthy individuals (mean age 31.5±8.5, 43 males and 24 females) were included in the study between January 2015 and June 2016 at the General Hospital of the PLA Rocket Force, with no HBV or hepatitis C virus (HCV) infection. From each participant, 2 ml EDTA anticoagulant blood and 5 ml non-anticoagulant blood was collected. The serum was used to assess the liver function by examining HBV serological markers and HBV DNA, and the anticoagulant blood was used to detect the expression of CD160 and lncRNA-CD160 in CD8+ T cells. The present study was approved by the Medical Ethics Committee of the General Hospital of the PLA Rocket Force (Beijing, China), and all individuals provided written informed consent.

Detection of CHB pathological index. The serum ALT and aspartate transaminase (AST) levels were measured using the rate method (13). The ‘rate method’, also termed continuous detection, is a method that continuously monitors the output (or consumption) of the product (or substrate) with a linear range at multiple detection points. All the normal reference intervals were 0-40 U/l. The serum level of total bilirubin was determined by a modified Malloy-Evelyn diazo method (14), and the normal reference interval was 0-21 µmol/l. Serum albumin was measured by the bromocresol green end point method (15), the normal reference interval was 34-48 g/l. HBsAg, hepatitis B surface antibody, HBeAb and hepatitis B virus c antibody were detected using a Roche Cobas 6000 immuno-chemiluminescence analyzer. HBV DNA load was detected by reverse transcription-quantitative PCR (RT-qPCR), and the threshold of detection was 500 copies/ml.

Purification of CD160. CD8+ T cells and CD160+ T cells. Peripheral blood mononuclear cells were isolated by Ficoll-Paque Plus (cat. no. 17-1440-03; GE Healthcare) using a FACSCalibur flow cytometer (BD Biosciences). Blood was added into the Ficoll-Paque Plus and centrifuged for 30 min at 1,500 x g and 20°C, then the isolated mononuclear cells were washed three times with PBS and cultured in RPMI-1640 medium (Hyclone; GE Healthcare) with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.). The cells were washed with FACS buffer (PBS containing FBS [2%; Atlanta Biologicals] and sodium azide [0.05%; Sigma-Aldrich; Merck KGaA]) and blocked with FACS buffer containing 10% FBS for 30 min at 4°C. Antibodies [CD8 (1:100; sc-1177; Santa Cruz Biotechnology, Inc.); CD160 antibody (1:1,000; AF3899; R&D Systems, Inc.)] specific for cell surface markers diluted in FACS buffer were added directly to this mixture and incubated for 30 min at 4°C. The cells were then washed with PBS and fixed by incubation with paraformaldehyde (4% in PBS; Electron Microscopy Sciences) for 10 min at room temperature. The cells were washed twice with permeabilization buffer (PBS with FBS [2%], sodium azide [0.05%], and saponin [0.1%; Sigma-Aldrich; Merck KGaA]) and blocked
with permeabilization buffer containing 10% FBS for 30 min at room temperature. CD8 (1:100) or CD160 (1:200) antibody diluted in permeabilization buffer were added directly to this mixture and incubated overnight (16 h) at 4°C. Then cells were washed 3 times with permeabilization buffer and PBS and resuspended in FACS buffer. The cells were kept on ice for 10 min until analysis using a LSR II flow cytometer (BD Biosciences), and analyzed using FlowJo software version 10.2 (BD Biosciences). Anti-CD8-FITC and anti-FITC magnetic beads, anti-CD160-PE and anti-PE magnetic microbeads were purchased from BD Biosciences.

Flow cytometry. Cells were harvested and centrifuged at 1,000 x g for 5 min and the supernatant was removed. A total of 5 ml PBS buffer was used to resuspend the cells, centrifuged (1,000 x g for 5 min) to discard the supernatant and repeated twice. Finally the cells were resuspended in 0.1 ml PBS and transferred to 1.5 ml centrifuge tubes. A total of 1 µl of each of the following primary antibodies were added to resuspend the cells and incubated at room temperature on the vertical mixture and incubated overnight (16 h) at 4°C. Then cells were centrifuged at 1,500 x g for 5 min, the supernatant was removed the supernatant and 1 ml PBS buffer was added to resuspend the cells. Cells were centrifuged (1,500 x g for 5 min) again to discard the supernatant, repeated three times and finally the washed cells were resuspended in 0.1 ml PBS. Fluorescent second antibody Alexa Fluor 488 (1:100; A32723; Thermo Fisher Scientific, Inc.) and Alexa Fluor 568 (1:100; A-11031; Thermo Fisher Scientific, Inc.) were added into the cell suspension and incubated at room temperature for 1 h. The cells were centrifuged at 1,500 x g for 5 min and the supernatant was removed and 1 ml PBS buffer was added to resuspend the cells. The cells were centrifuged (1,500 x g for 5 min) again to discard the supernatant, repeated three times and finally the cells were resuspended in 0.2 ml PBS. FACScan flow cytometry (BD LSRII FlowFortessa X-20; BD Biosciences) was used to analyze the cell count and FlowJo version 10 (BD Biosciences) was used for analysis of the data.

Enzyme-linked immunosorbent assay (ELISA). The concentrations of cytokines TNF-α and IFN-γ were measured by sandwich ELISA using a Human TNF-α ELISA kit (ab18421; Abcam) and Human IFN-γ ELISA Kit (ab174443; Abcam) according to the manufacturer's protocols. Data were acquired using a SpectraMax i3x microplate reader (Molecular Devices, LLC) at 450 nm. The concentration of each cytokine was assessed by the optical density value, and cytokine concentrations were extrapolated into the standard dilution curve at pg/ml.

RNA isolation, RT-qPCR, chromatin immunoprecipitation (ChIP)-qPCR and RNA immunoprecipitation (RIP)-qPCR. Total RNA was isolated from CD160+ CD8+ T cells and CD160− CD8+ T cells using the RNeasy Mini kit (Qiagen, Inc.) and SuperScript III Reverse Transcriptase (Thermo Fisher Scientific, Inc.) was used to generate complementary DNA (cDNA). qPCR was performed using SYBR Green Master mix (Roche Diagnostics) and a 7300 Real-Time PCR system (Invitrogen; Thermo Fisher Scientific, Inc.). The gene expression data were normalized to the level of GAPDH. The qPCR conditions were as follows: 95°C for 10 min, followed by 40 amplification cycles at 95°C for 30 sec to denaturation and a final step at 60°C for 1 min. The 2−ΔΔCq method (15) was used to analyze the relative abundance of RNA. The ChIP assay was conducted with 5x10⁶ CD160+ CD8+ T cells or CD160− CD8+ T cells using a ChIP assay kit (EMD Millipore), according to the manufacturer's protocol. RIP was conducted using a Magna RIP-Binding Protein Immunoprecipitation kit (EMD Millipore), according to the manufacturer's protocol. Following ChIP and RIP, qPCR was performed as aforementioned. The primers were used as follows: HDAC11 forward, 5'-GCTCACCCAGGAAATGGACA-3' and reverse, 5'-AAT ACCTCCTCGCTACAC-3'; IFN-γ forward, 5'-CAAGTG ATGGCTGAACTGTGCG-3' and reverse, 5'-CCTTGAAAC AGCATCGACTACG-3'; TNF-α forward, 5'-ACACGAC CTGAGACACAGAC-3' and reverse, 5'-TCGCCCAGGAAATCA GTAGA-3'.

lncRNA microarray analysis. CD160+ CD8+ T cells and CD160− CD8+ T cells were isolated from peripheral blood mononuclear cells as aforementioned. The total RNA of CD160+ CD8+ T cells and CD160− CD8+ T cells was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The extracted RNA was labeled with fluorescent probes with a Quick Amp Labeling kit (Agilent Technologies, Inc.) and quantified using NanoDrop ND-1000 and RNeasy Mini kit (Qiagen, Inc.). Subsequently, the Agilent Gene Expression Hyridization kit (Qiagen, Inc.) was used to hyridize the RNA. An Agilent Scanner G2505C (Agilent Technologies, Inc.) and Agilent Feature Extraction software (version 10.5.1.1; Agilent Technologies, Inc.) were used to scan the fluorescent intensity and evaluate the expression levels of lncRNA in CD160+ CD8+ T cells and CD160− CD8+ T cells. Finally, the lncRNA data were analyzed by functional annotation using Gene Set Enrichment Analysis software (Broad Institute, Inc.).

Small interfering (si)RNA transfection assay. For knockdown of CD160 in CD8+ T cells, CD160-siRNA and HDAC11-siRNA were purchased from GenePharma and the siRNA were transfected using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific) according to the manufacturer's protocol. The 6-wells plates were used for siRNA transfection assays. For the each well, 500 ng siRNAs was added into 10 μl Lipofectamine® 2000 according to the manufacturer's protocol and then were incubated with CD8+ T cells for 48 h. Then the siRNAs were removed and CD8+ T cells were collected for the CD160 or HDAC11 knockdown experiments. The sequences of siRNA were as follows: The universal and scrambled negative control siRNA, 5'-UUCUCCGAACGUGUCACGUTT-3'; CD160 siRNA, 5'-AGGAUUAUGCCCAUUGGACGC-3'; HDAC11 siRNA, 5'-UCUGCAUCCAGAGCCCAUUCG-3'. Alternatively, to establish a stable CD8+ T cell line with low expression levels of lncRNA-CD160 and provide a stable CD160+ CD8+ T cell line to establish of animal models, lentivirus (LV)-mediated knockdown of lncRNA-CD160 was performed using a LV vector pGLVU6/GFP (Shanghai GenePharma Co., Ltd.) encoding GFP and siRNA targeting lncRNA-CD160 (LV-lncRNA-CD160) using 5 ng/ml Polybrene.
IncRNA pull-down assay. IncRNA-CD160 was biotin-labeled using a Biotin RNA Labeling mix (Roche Diagnostics) and a pSPT19 vector expressing IncRNA-CD160 purchased from GenePharma. IncRNA-CD160 transcription was performed using SP6 RNA polymerase (Promega Corporation) and pSPT19 vector expressing IncRNA-CD160 (Shanghai GenePharma Co., Ltd.) according to the manufacturer’s protocol (16). CD8+ T cells were treated with RNase-free DNase I (Roche Diagnostics) and purified using an RNasy Mini kit (Qiagen, Inc.). Subsequently, the nuclear proteins, which was isolated from CD8+ T cells extracts using a Cytoplasmic and Nuclear RNA purification kit (Norgen Biotek Corp.), were mixed and incubated with biotin-labeled IncRNA-CD160 at 37°C for 2 h. Followed by further incubation with streptavidin-conjugated agarose beads (Invitrogen; Thermo Fisher Scientific, Inc.) and washed three times using PBS. The retrieved proteins were detected by western blot analysis.

Western blotting. CD8+ T cells were lysed for 30 min in RIPA lysis buffer (P0013B; Beyotime Institute of Biotechnology) on ice and centrifuged at 15,000 x g for 20 min at 4°C. Total protein concentration were detected by BCA (Beyotime Institute of Biotechnology), and protein per lane were loaded onto a 15% gel, resolved using SDS-PAGE and subsequently transferred onto PVDF membranes. Membranes were blocked using 5% fat-free milk in PBST (0.05% Tween20 in PBs) for 30 min at room temperature. Incubating primary antibodies by overnight incubation at 4°C, followed the HRP-conjugated secondary antibodies incubation for 1 h at 37°C. The following antibodies were used: CD160 (1:500; ab202845; Abcam), HDAC11 (1:300; sc-390737; santa Cruz Biotechnology), GAPDH (1:1,000; sc-365062; Santa Cruz Biotechnology), pSTAT3 (1:1,000; sc-287722; Santa Cruz Biotechnology), and rabbit IgG (1:5,000; sc-20040; Santa Cruz Biotechnology). Bound antibodies were detected using BeyoECL Plus reagent kit (Advansa Inc) according to the manufacturer’s instructions. Images were developed using OPTIMAX X-Ray film processor (Optimax 2010; Protec GmbH & Co. KG).

Northern blotting. The total RNA was isolated from CD8+ T cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The enriched RNA samples (10 µg) were loaded onto a 15% gel, resolved using SDS-PAGE and subsequently transferred onto Biodyne Nylon membranes (Pall Corp.). The sequence of the digoxigenin-labeled (Roche Diagnostics) IncRNA-CD160 cDNA probe for Northern blot analysis was as follows: 5’-TTAGTTCCCTTTGGGTCGGCGGCGGCCGAACCAACAGGAACATCTCGGAAGTTACCGGTTGGTCGATGTCTCGTGTAGTGCGGTTGGCAGGAAATCTAATCGAACGCCGCCGGA

RNA fluorescence in situ hybridization (FISH). FISH experiments were performed with the IncRNA-CD160 (sequence: 5’-GACTAATGACATGCAACTGCT-3’) and HDAC11 (sequence: 5’-GGACCTGCAATCCGGATGTGGGATCACAGT-3’) probes were purchased from GenePharma Co., Ltd. CD8+ T cells isolated from the peripheral blood mononuclear cells of patients with chronic HBV infection were fixed in 4% paraformaldehyde at 4°C for 16 h and then suspended in PBS buffer, then the solution was centrifugated (10,000 x g, 4°C, 10 min) and the pellets were collected from centrifugation and resuspended in 10 ml of sodium pyrophosphate solution (3.8 mM). The suspension was diluted to 10^-10 CFU/ml and 20 µl of this dispersed sample was dropped onto a poly-L-Lysine-coated slide. The slide was air-dried at 37°C for 2 h and then dehydrated using 50, 80 and 100% ethanol each for 3 min. The slides were incubated at 37°C for 30 min in 50 µl lysosome solution (10 ng/ml), washed with sterile distilled water and then dehydrated using the ethanol dehydration series as aforementioned and air-dried. Hybridization was performed at 42°C for 2 h with hybridization buffer [0.9 M NaCl, 20 mM Tris-HCl (pH 7.4), 0.01% (w/v) SDS] and 0.5 ng/µl of the digoxigenin-labeled probe (IncRNA-CD160 and HDAC11; Shanghai GenePharma Co., Ltd.) was added into the hybridization buffer, in which different concentrations [for IncRNA-CD160 probe, 20% (w/v); for HDAC11 probe, 25% (w/v)] of formamide were added. Slides were washed twice in 50 ml prewarmed washing buffer [20 mM Tris-HCl (pH 7.2), 10 mM EDTA, 0.01% (w/v) SDS, 0.3 M NaCl] at 48°C for 30 min and subsequently washed with distilled water and air-dried in the dark after hybridization. The slides were incubated with DAPI dye for 10 min at room temperature and washed 3 times with PBS. Finally, the slides were mounted in an anti-fade solution for 2 h at room temperature and observed using a fluorescence microscope (BX-51; Nikon) with excitation 534-558 nm at a magnification of x1,000.

Animal experiment. All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee of Institute of Zoology (Chinese Academy of Sciences) and the animal experiments were approved by The Medical Ethics Committee of the General Hospital of the PLA Rocket Force (Beijing, China). C3H/HeN mice (n=30; 15 males and 15 females; 6 week old, weighing 18-22 g) were purchased from Cyagen Biosciences. The animals were housed at 24-28°C with 50-60% humidity and ventilation 10-15 times/h and natural circadian light. The food was sterilized using irradiation and water was treated with bacitracin (4 g/l) and neomycin (4 g/l). The food and water was provided ad libitum. Twenty mice were injected with 10 mg pAAV-HBV 1.2 plasmid (Shanghai GenePharma Co., Inc.). After 24 days, the CD160-CD8+ T cells which were now at their third passage were collected for detection of transfection efficiency. The transfection efficiency was evaluated using RT-qPCR for RNA expression detection or flow cytometry for the determination of GFP-positive cells. The sequence of IncRNA-CD160 siRNA was 5’-UUTTCAGTCATGUAUTTCAAT-3’ and the sequence of the universal scrambled negative control siRNA (used for both transfection methods) was 5’-UUUCUGGACGUAGCAGGUUU-3’.

RNA analysis was as follows: 5’-TAGTTCCCTTTGGGTCGGCGGCGGCCGAACCAACAGGAACATCTCGGAAGTTACCGGTTGGTCGATGTCTCGTGTAGTGCGGTTGGCAGGAAATCTAATCGAACGCCGCCGGA
HBV infection was calculated using Spearman's rank correlation analysis. P<0.05 was considered to indicate a statistically significant difference.

Peripheral blood samples were collected at room temperature. The sections were then incubated at 4˚C with the corresponding secondary goat anti-mouse IgG-HRP complexes were visualized using DAB and counterstained with hematoxylin at room temperature for 5 min. Finally, the sections were dehydrated in ethanol (50, 75, 85 and 95%) series, cleared in xylene, and examined using microscope (magnification, x400; BX-51; Nikon). The number of CD160 positive cells in one view were counted and this was repeated 3 times. In all staining procedures, the positive controls showed clear staining, whereas there was no staining in the negative controls.

Statistical analysis. All data are presented as the mean ± standard deviation of triplicate experiments and analyzed using SPSS 19.0 (IBM, Corp.). Two-way analysis of variance followed by Bonferroni's post hoc test was used to compare different groups. Student's t-test or Mann-Whitney U test was used to compare two means. The correlation between the percentage of peripheral blood CD160+ CD8+ T cells and HBV infection was calculated using Spearman's rank correlation analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

CD160+ CD8+ T cells in CHB patients negatively mediate the progress of CHB. Peripheral blood samples were collected from patients with CHB and healthy individuals, and the isolated serum was assessed for liver function, HBV serological markers and HBV DNA. No significant differences in the sex and age were identified between patients and healthy controls group. The clinical data of each group is presented in Table I. The mean age, ALT, AST, HBsAg and HBV DNA were significantly different in the IT stage group compared with the IC stage groups; moreover, a significant difference has been indicated for same indexes between the IC group and LR group. Furthermore, the percentage of CD160+ CD8+ T cells in the peripheral blood of CHB patients was significantly higher compared with the healthy population (Fig. 1A). The results indicated that the percentage of CD160+ CD8+ T cells in the peripheral blood of CHB patients with IT stage was significantly higher compared with the healthy group and patients with IC or LR stage, while there was no significant difference between IC and LR stage, which indicates that CD160 was activated in CHB patients (Fig. 1B and C). In order to detect the role of CD160 in the CD8+ T cell function of anti-immunity, (SLAM)-associated protein (sAP) was detected, which is a potential downstream protein of CD160. Peripheral blood mononuclear cells (PBMCs) from CHB patients were transfected with CD160-siRNA and control siRNA; the results revealed that the percentage of sAP+ CD8+ T cells was associated with the expression of CD160 as transfection with CD160 siRNA significantly decreased the percentage of CD160+ CD8+ T cells and SAP+ CD8+ T cells (Fig. 1D-G). These data indicate that SAP is associated with CD160 in CD8+ T cells during CHB infection. Furthermore, the present study also detected the role of CD160 in the function of CD8+ T cells; the data demonstrated that CD160 siRNA could significantly decrease the concentration of IFN-γ and TNF-α in the supernatants of CD8+ T cells, which were isolated from CHB patients (Fig. 1H and I). These data indicated that CD160 serves an important role in cytokine production in CD8+ T cells of CHB patients.

CD160 inhibits histone-modification enzyme gene histone deacetylases 11 (HDAC11) expression through epigenetic regulation. In order to detect whether CD160 expression could alter the expression of related regulatory molecules in HBV infection, CD160+ CD8+ T cells and CD160- CD8+ T cells were isolated from PBMCs in CHB patients, and the cells were used for gene microarray analysis (Fig. 2A). The results demonstrated that HDAC11 expression was higher in CD160+ CD8+ T cells compared with in CD160- CD8+ T cells (Fig. 2B). Further RT-qPCR analysis confirmed that the expression of HDAC11 in CD160+ CD8+ T cells was significantly higher compared with in CD160- CD8+ T cells (Fig. 2C). The confocal microscopic images of HDAC11 and CD160 in the immunofluorescence assay confirmed that HDAC11 and CD160 were expressed in CD160+ CD8+ T cells (Fig. 2D). As HDAC11 can mediate trimethylate H3K9Me1, which is a marker of gene silencing (17), the present study detected the HDAC11 expression in CD160+ CD8+ T cells and CD160+ CD8+ T cells. siRNA transfection assays indicated that CD160 could inhibit the expression of HDAC11 (Fig. 2E). Furthermore, HDAC11 protein expression levels were detected using western blotting, which was negatively associated with the expression of CD160 (Fig. 2F). Additionally, the effect of HDAC11 siRNA was detected using western blotting (Fig. 2G) and the mRNA expression levels of IFN-γ and TNF-α were
significantly inhibited when HDAC11 was knocked down (Fig. 2H and I). Furthermore, among the total CD8+ T cells, the percentages of HDAC11+ CD160- CD8+ T cells and HDAC11+ CD160+ CD8+ T cells were significantly higher compared with HDAC11- CD160+ CD8+ T cells and HDAC11+ CD160+ CD8+ T cells, respectively (Fig. 2J). These results suggested that the expression of HDAC11 in CD160+ CD8+ T cells was higher than the expression in the CD160- CD8+ T cells, and the depletion of HDAC11 could decrease the expression of IFN-γ and TNF-α, which indicated that HDAC11 acts as a promoter of IFN-γ and TNF-α expression, and CD160 is negatively mediated by HDAC11 expression in CD8+ T cells with HBV infection.

**Table I. Clinical data of patients with chronic hepatitis B infection.**

| Variable                  | Healthy individuals (n=67) | Patients with chronic hepatitis B infection (n=164) |
|---------------------------|-----------------------------|-----------------------------------------------------|
| Age, years                | 31.5±8.5                    | 23.5±6.0                                            |
| Sex, n, male/female       | 43/24                       | 23/22                                               |
| ALT, U/l                  | 9.42±4.87                   | 31.61±9.39                                          |
| AST, U/l                  | 8.63±3.64                   | 31.16±8.38                                          |
| Total bilirubin, µmol/l   | 9.37±3.81                   | 21.02±7.11                                          |
| Albumin, g/l              | 38.23±9.13                  | 48.18±11.23                                         |
| HBsAg, S/CO               | <1.00                       | 2.017.34±242.85                                     |
| HBsAb, n, +/-             | 0/67                        | 0/61                                                |
| HBeAg, S/CO               | <1.00                       | 942.63±87.03                                        |
| HBeAb, n +/-              | 0/67                        | 0/45                                                |
| HBeAg, n +/-              | 0/67                        | 45/0                                                |
| HBV DNA, copy/ml          | <1.0×10^3                   | 8.24×10^7±4,831.26                                  |

^4P<0.05 vs. IT stage; ^5P<0.05 vs. IC stage. S/CO: S, Sample absorbance; CO, CUT OFF, namely critical value. S/CO<1.0 represents the positive, and S/CO≥1.0 represents the negative. ALT, alanine aminotransferase; AST, aspartate transaminase; HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HBeAg, hepatitis B virus e antigen; HBeAb, hepatitis B virus e antibody; HBcAb: Hepatitis B virus c antibody, HBV, hepatitis B virus; IT, immune tolerance; LR, low- replicate; IC, immunological clearance.

**In conclusion,** HDAC11 expression in CD160+ CD8+ T cells was significantly higher compared with that in CD160+ CD8+ T cells. In order to detect whether IncRNA-CD160 could mediate IFN-γ and TNF-α secretion in CD8+ T cells during HBV infection, CD8+ T cells isolated from patients with CHB were transfected with CD160-siRNA and ChIP was performed. The results revealed that HDAC11 and H3K9Me1 trimethylation loci, which could negatively mediate transcription, were significantly increased in IncRNA-CD160 loci following CD160-siRNA transfection (Fig. 3E and F). These results indicated that CD160 inhibited the expression of IncRNA-CD160, and IncRNA-CD160 was activated in CD160+ CD8+ T cells. Furthermore, IncRNA-CD160 also negatively regulated HDAC11 and H3K9Me1 in IncRNA-CD160 loci.

**IncRNA-CD160 increases the expression of IFN-γ and TNF-α in CD8+ T cells.** In order to detect whether IncRNA-CD160 could mediate IFN-γ and TNF-α secretion in CD8+ T cells during HBV infection, CD8+ T cells isolated from patients with CHB were transfected with IncRNA-CD160 siRNA targeted to IncRNA-CD160 and the efficiency of IncRNA-CD160 siRNA was detected using RT-qPCR (Fig. 4A). In CD8+ T cells, IncRNA-CD160 siRNA transfection was performed and the secretion of IFN-γ and TNF-α were significantly increased, which suggested that IncRNA-CD160 may exert a negative effect on the secretion of IFN-γ and TNF-α in CD8+ T cells (Fig. 4B and C). To further investigate the mechanism of IncRNA-CD160 on the inhibition of IFN-γ and TNF-α secretion, CHIP-qPCR was performed, and the results indicated that H3K9Me1 expression levels at the IFN-γ and TNF-α promoter loci were significantly inhibited following IncRNA-CD160 siRNA transfection (Fig. 4D and E). To detect the association between IncRNA-CD160 and HDAC11, the immunoprecipitation of HDAC11 was performed with CD8+ T cells, and the results revealed that HDAC11-specific mAb could co-purify with IncRNA-CD160 (Fig. 4-I). Furthermore, the FISH data indicated that following IncRNA-CD160 siRNA transfection,
lncRNA-CD160 and HDAC11 were located at the same location and lncRNA-CD160 could inhibit the expression of HDAC11 (Fig. 4J). Additionally, the western blot assay demonstrated that lncRNA-CD160 could specifically bind to HDAC11 (Fig. 4K). The results of RNA FISH revealed that lncRNA-CD160 co-localized with HDAC11 in the nucleus of CD8+ T cells that were isolated from patients with CHB (Fig. 4L). These data indicated that lncRNA-CD160 and HDAC11 could form copolymers and regulate the transcription of HDAC11. Furthermore, according to CHIP-qPCR assay, when CD8+ T cells were transfected with lncRNA-CD160 siRNA, the expression levels of HDAC11 in total CD8+ T cells was inhibited. To further clarify the role of CD160 in the CD8+ T cell immune response, the concentrations of (H) IFN-γ and (I) TNF-α were detected, which are produced by CD8+ T cells. IFN-γ and TNF-α were significantly decreased following CD160-knockdown in CD8+ T cells. **P<0.01, ***P<0.005. HBV, hepatitis B virus; CHB, chronic HBV; siRNA, small interfering RNA; SAP, (SLAM)-associated protein con, control; IT, immune tolerance; LR, low-replicate; IC, immunological clearance.

lncRNA-CD160 is crucial for suppression of HBV replication in CD8+ T cell immune response during in vivo HBV infection. In order to determine the effect of lncRNA-CD160 on the immune response of CD8+ T cells during HBV infection in vivo, an adoptive transfer model was used to detect the role of lncRNA-CD160, and inhibition of lncRNA-CD160 expression was achieved by LV-mediated transfection (Fig. 5A). Following adoptive transfer, the serum HBsAg levels were detected at different time points, and the results revealed that after the mice were transfected, the serum HBsAg level was
significantly lower at days 4-14 compared with those transfected with the LV-Control (Fig. 5B). In addition, the serum HBV DNA copy number was also significantly lower in the LV-lncRNA-CD160 transfected mice compared with in the LV-Control transfected mice at days 4-11 days post-adoptive transfer (Fig. 5C). Furthermore, the expression levels of...
HBcAg were detected and the percentage of HBcAg-positive hepatocytes was evaluated. The results indicated that LV-lncRNA-CD160 could significantly inhibit the expression of HBcAg in vivo compared with the controls (Fig. 5D and E). These data suggest that lncRNA-CD160 suppression in CD8+ T cells could significantly inhibit HBV infection compared with lncRNA-CD160-expressing CD8+ T cells, suggesting that lncRNA-CD160 serves an important role in CD8+ T cell immune response during in vivo HBV infection.

The mechanism underlying the lncRNA-CD160 in CD8+ T cell immune response during HBV infection. In CD160+ CD8+ T cells, lncRNA-CD160 could inhibit the secretion of IFN-γ and TNF-α through HDAC11 recruitment. lncRNA-CD160 and HDAC11 bind to form a complex on the promoters of IFN-γ and TNF-α, which enhances the methylation of H3K9Me1. Subsequently, chromatin is converted into heterochromatin and the transcription of IFN-γ and TNF-α is blocked, which inhibits the secretion of IFN-γ and TNF-α. Furthermore, the
Wu et al.: lncRNA-CD160 DECREAsES THE IMM unITY oF CD8+ T CELLS

Figure 4. lncRNA-CD160 inhibits IFN-γ and TNF-α secretion in CD8+ T cells via epigenetic regulation. In order to demonstrate the role of lncRNA-CD160 on IFN-γ and TNF-α secretion, siRNA targeting lncRNA-CD160 was transfected into the CD8+ T cells. (A) The efficiency of lncRNA-CD160 siRNA was detected, and the concentrations of (B) IFN-γ and (C) TNF-α were detected by ELISA assay. A CHIP-qPCR assay was performed to demonstrate the mechanism of the IFN-γ and TNF-α secretion inhibition. When lncRNA-CD160 was knocked down, the H3K9Me1 expression levels, which could be mediated by HDAC11 at the (D) IFN-γ and (E) TNF-α promoters loci, were significant inhibited. (F) Immunoprecipitation and western blot assays were performed to detect the expression of HDAC11 in the immunoprecipitate using an anti-HDAC11-specific antibody. (G) Gel electrophoresis and (H) an image of biotinylated lncRNA-CD160. (I) Reverse transcription-qPCR analysis of lncRNA-CD160 retrieved by IgG or anti-HDAC11 from CD8+ T-cell lysates of patients with HBV. (J) FISH following lncRNA-CD160 siRNA transfection, magnification, x1,000. (K) RNA pull-down and western blot assays were conducted to investigate the association between lncRNA-CD160 and HDAC11, and the data indicated that lncRNA-CD160 and HDAC11 could bind to each other. (L) Further RNA FISH and immunofluorescence analyses were performed to investigate the locations of lncRNA-CD160 and HDAC11, and the results demonstrated that both were located in the nucleus of CD8+ T cells, magnification, x1,000. A CHIP-qPCR assay was also performed to reveal the location of the lncRNA-CD160 and HDAC11 complex, and the results revealed that lncRNA-CD160-siRNA could significantly inhibit the expression of HDAC11 at (M) IFN-γ and (N) TNF-α promoter regions. **P<0.01, ***P<0.005. FISH, fluorescent in situ hybridization; lncRNA, long non-coding RNA; con, control; siRNA, small interfering RNA; qPCR, quantitative PCR; HDAC11, histone-modification enzyme gene histone deacetylases 11.
lncRNA-CD160-targeted siRNA could block the complex formation of lncRNA-CD160 and HDAC11 (Fig. 5F).

Discussion

The transfer and development of chronic HBV infection is associated with the immune response (20). If a patient with HBV infection cannot effectively produce a specific immune response, the disease will become immune tolerant and chronic HBV infection will occur (21). One possible strategy for the treatment of chronic HBV infection is to reverse the immune tolerant status of patients with CHB infection and promote the recovery of specific immune responses (22).

Figure 5. lncRNA-CD160 suppresses HBV replication during infection in vivo. (A) To investigate the effect of lncRNA-CD160 on HBV replication, an adoptive transfer model was established. (B) Following adoptive transfer, the serum HBsAg levels were detected at different time points using a Roche Cobas 6000 immuno-chemiluminescence analyzer. *P<0.05, ***P<0.005 vs. LV-lncRNA-CD160. (C) The HBV DNA load was detected by reverse transcription-quantitative PCR assay at different time points following adoptive transfer. *P<0.05, ***P<0.005 vs. LV-lncRNA-CD160. (D) An immunohistochemistry assay was performed for HBcAg detection in the liver tissues, which were harvested from the adoptive transfer model mice, magnification, x1,000. (E) The percentages of HBcAg-positive hepatocytes were quantified. *P<0.01 and ***P<0.005. (F) An overview of the role of lncRNA-CD160 in the mediation of IFN-γ and TNF-α. lncRNA, long non-coding RNA; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; LV, lentivirus; HBcAg, hepatitis B virus c antibody; SAP, (SLAM)-associated protein; siRNA, small interfering RNA.
CD160 is a GPI-fixed membrane protein, which is located in chromosome 1q42.3, and is mainly expressed in NK cells and T cell subsets (23). The physiological function of CD160 is low affinity binding to MHC I molecules; however, it also binds with high affinity to MHC class II molecules (24). CD160 bound to MHC class II can directly and indirectly inhibit the proliferation of T cells and the secretion of related factors, which contributes to negative immune regulation (25). In the process of chronic viral infections, such as HBV, human immunodeficiency virus (HIV) and HCV, T cell response cannot effectively control virus replication due to the depletion of antiviral CD8+ T cell function (26). Important markers for the depletion of T cell function are high expression levels of PD-1, LAG-3 and CD160, which are co-inhibitory molecules on the surface (27). The percentage of CD160+ CD8+ T cells in the peripheral blood of patients with HIV is significantly increased, and is positively correlated with disease progression; CD160 inhibition can significantly enhance HIV-specific T cell responses (28). In antiretroviral treatment, high expression levels of CD160 is a predictor of poor efficiency of HIV treatment (29). These previous reports demonstrated that CD160 serves an important role in the maintenance of antiviral immune tolerance. However, the changes of CD160 expression in T cells of patients with CHB, and the association between these changes and chronic infection status have not been reported.

Based on the complex interaction between the virus and homeostasis of human body, the natural history of chronic HBV infection can be divided into three distinct stages (11,12). At each stage, the host's antiviral immune response often determines the duration of infection and the severity of liver injury. The present study found that the highest percentage of peripheral blood CD160+ CD8+ T cells appeared in the IT stage of chronic HBV infection, was significantly higher compared with the other stages, and was directly positively correlated with the level of HBeAg in serum. During the IT phase of CHB infection the body does not produce an immune response to HBV antigen, and cannot effectively identify and clear the virus, which results in a state of HBV replication (30). Although the pathological mechanism in the IT stage is complex, the continued exposure of T cells to high levels of virus antigen is the main reason for T cell depletion and a low response state of HBV-specific T cells in HBV infection (31). The present study found that in the IT phase of HBV infection, the expression of CD160 in CD8+ T cells was negatively associated with IFN-γ and TNF-α secretion. Furthermore, according to the microarray assay, it was identified that the expression level of HDAC11 was negatively associated with CD160, and is also located in the nucleus. Since CD160 is a membrane protein, and IFN-γ and TNF-α are transcribed in the nucleus, the present study conducted further research to investigate how CD160 affects the secretion of IFN-γ and TNF-α.

IncRNAs are non-coding RNAs with lengths >200 nucleotides, and previous reports have demonstrated that IncRNA serves important roles in epigenetic regulation, cell cycle regulation, cell differentiation regulation and many other activities (32-34); therefore, it has become the focus of genetic research (35). The present study conducted a IncRNA microarray and found that the expression level of IncRNA-CD160 in CD160 CD8+ T cells was significantly higher compared with that in CD160+ CD8+ T cells, and IncRNA-CD160 was also located in Chr1q42.3, across the B and C region of CD160; therefore it was termed IncRNA-CD160. Further experiments demonstrated that IncRNA-CD160 and HDAC11 could form a copolymer, and anchored at the IFN-γ and TNF-α promoters to promote H3K9Me1 methylation, thereby resulting in abnormal chromatin, which blocked the transcription and translation of IFN-γ and TNF-α, while IncRNA-CD160 siRNA could reverse this phenomenon. In vivo experiments also revealed that in HBV infected mice, IncRNA-CD160-knockdown CD8+ T cells could significantly inhibit the replication of HBV virus and promote the immune response of HBV-specific CD8+ T cells.

In conclusion, IncRNA-CD160 acts as an immune suppressive factor, and is expressed at a high level in peripheral blood CD8+ T cells of HBV infected patients, particularly in patients with IT stage HBV infection. Furthermore, a high expression of IncRNA-CD160 can contribute to the inhibition of IFN-γ and TNF-α secretion in CD8+ T cells, and decrease the immune response of CD8+ T cells. Therefore, IncRNA-CD160 may become a new target for immunotherapy of CHB infection in the future, which may provide a new therapeutic strategy for the treatment of HBV infection.

Acknowledgements

Not applicable.

Funding

The current study was supported by the 12th Five-Year Scientific Research Project of the People's Liberation Army (grant no. D101100050010042).

Availability of data and materials

All data generated or analyzed during the present study are included in this published article.

Authors' contributions

JW contributed to the conception, design, writing and revision of the manuscript. QN and JY collected and analyzed the data. XX and LC contributed to the analysis and interpretation of data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All patients provided written informed consent and agreed to the usage of their samples in scientific research. All human procedures were approved by The Ethics Committee of General Hospital of the PLA Rocket Force (Beijing, China). All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of General Hospital of the PLA Rocket Force and the experiments were approved by The Animal Ethics Committee of General Hospital of the PLA Rocket Force.

Patient consent for publication

Not applicable.
Competing interests

The authors declare that they have no competing interests.

References

1. Lok AS, McMahon BJ, Brown RS Jr, Wong JB, McMahon BJ Jr, Wong JB, Ahmed AT, Martin P, Dubois C, Jacquier E, Dion, Mancini-Bourgine M, Godin O, Khatrizer R, Lelu-Santolaria K, Evlachev A, Mietiet JF, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 64: 1961-1971, 2015.

2. Ye B, Lin X, Dong Y, Wang Y, Tian L, Lin S, Liu X, Kong H and Chen Y: Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent. Medicine (Baltimore) 96: e5275, 2017.

3. Yang Z, Lei Y, Chen C, Ren H and Shi T: Roles of the programmed cell death 1, T cell immunoglobulin mucin-3, and cluster of differentiation 28 pathways in the low reactivity of invariant natural killer T cells after chronic hepatitis B virus infection. Arch Virol 160: 2535-2545, 2015.

4. Raitzourrhou B, Heeg M, Kurktschiev P, Schraut W, Arch Virol 160: 2535-2545, 2015.

5. Hakim MS, Spann M, Janssen HL and Boonstra A: Inhibitory receptor molecules in chronic hepatitis B and C infections: Novel targets for immunotherapy? Rev Med Virol 24: 125-138, 2014.

6. Ma L, Chua MS, Andrisani O and So S: Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives. World J Gastroenterol 20: 333-345, 2014.

7. Niu J, Lin Y, Liu P, Yu Y, Su C and Wang X: Microarray analysis on the IncRNA expression profile in male hepatocellular carcinoma patients with chronic hepatitis B virus infection. Oncotarget 7: 76196-76180, 2016.

8. Steinberg MW, Cheung TC and Ware CF: The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol Rev 244: 169-187, 2011.

9. Cai G and Freeman GJ: The CD160, BTLA, LIGHT/HVEM pathway: A bidirectional switch regulating T-cell activation. Immunol Rev 229: 244-258, 2009.

10. Chinese Society of Hepatology, Chinese Medical Association: Chinese Society of Infectious Diseases, Chinese Medical Association: The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 13: 881-891, 2005 (In Chinese).

11. European Association of the Study of the Liver: 2011 European Association of the study of the liver hepatitis C virus clinical practice guidelines. Liver Int 32 (Suppl 1): S2-S8, 2012.

12. Tan PC, Aziz AZ, Ismail IS and Omar SZ: Gamma-glutamyltransferase, alanine transaminase and aspartate transaminase levels and the diagnosis of gestational diabetes mellitus. Clin Biochem 45: 1192-1196, 2012.

13. Parvianen MT: A modification of the acid diazo coupling method (Malloy-Evelyn) for the determination of serum total bilirubin. Scand J Clin Lab Invest 57: 275-279, 1997.

14. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the δ-Delta Delta CT (ΔΔCT) method. Methods 25: 402-428, 2001.

15. Jilalian S, Teimoon A, Makvandi M and Zandi M: An in vitro transcription assay for development of rotavirus VP7. Iran J Microbiol 9: 186-194, 2017.

16. Sui L, Zhang S, Huang R and Li Z: HDAC11 promotes meiotic apparatus assembly during mouse oocyte maturation via decreasing H4K16 and α-tubulin acetylation. Cell Cycle 19: 354-362, 2020.

17. Bhan A, Hussain I, Ansari KI, Kasiri S, Bashyal A and Mandal SS: Antisense transcript long noncoding RNA (IncRNA) HOTAIR is transcriptionally induced by estradiol. J Mol Biol 425: 3707-3722, 2015.

18. Zhou HL, Luo G, Wise JA and Lou H: Regulation of alternative splicing by local histone modifications: Potential roles for RNA-guided mechanisms. Nucleic Acids Res 42: 701-713, 2014.

19. Bertoletti A and Ferrari C: Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection. Postgrad Med J 89: 294-304, 2013.

20. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, et al: Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 146: 1240-1248, 2014.

21. Bertoletti A and Kennedy PT: The immune tolerant phase of chronic HBV infection: New perspectives on an old concept. Cell Mol Immunol 12: 258-263, 2015.

22. Chen K, Lin C, Wang S, Weatherburn C, Ho PJ, Woodland N, Nassif N, Barbaro P, Bryant C, Hart D, et al: Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30: 1716-1724, 2016.

23. Ortonne N, Ram-Wolf C, Giustiannia J, Marie-Cardine A, Bagot M, Mecheri S and Bensussan A: Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160. J Invest Dermatol 131: 916-924, 2011.

24. Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stotzner P, Willenbacher E, Greil R and Jöhner K: T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol 9: 116, 2016.

25. Russell CD, Unger SA, Walton M and Schwarz Z: The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev 30: 481-502, 2017.

26. Perl A, Fernandez DR, Telarico T, Doherty E, Francis L and Phillips PE: T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol 21: 454-464, 2009.

27. Fromentin R, Bakeman W, Lawani MB, Khouyr G, Hartogensis W, Da Fonseca S, Killian M, Epling L, Hoh R, Sinclair E, et al: CD4+ T cells expressing PD-1+ expression but absent coregulation of multiple inhibitory molecules. PLoS One 9: e105703, 2014.

28. Ouyang J, Hu J and Chen JL: lncRNAs regulate the innate immune response to respiratory syncytial virus infection. Respirology 21 (Suppl 1): 11-18, 2016.